Clinical Trials Directory

Trials / Completed

CompletedNCT02593942

Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy

Effect of Remifentanil Infusion Alone During the Closure Period for Early Emergence and Hemodynamic Stability in Patients Undergoing Supratentorial Craniotomy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Yeditepe University Hospital · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Total intravenous anaesthesia using propofol and remifentanil are routinely used drugs for this purpose. The hemodynamic stability and at the same time early emergency are the main goals following neurosurgery. However there is no standard for discontinuation time for manually controlled systems today. The investigators aimed to study the effect of remifentanil infusion alone for early emergence and hemodynamic stability during the closure period in patients undergoing supratentorial craniotomy.

Detailed description

Adult, American society of Anaesthesiologist score I-II, 80 patients who underwent elective supratentorial craniotomy for tumour resection were randomly assigned to group I or II. In group I; propofol was discontinued during the dural closure. After the propofol was discontinued, remifentanil dose was increased with the guidance of bispectral index spectrum and hemodynamic parameters. In group II; propofol discontinued before the end of the surgery. Time to awakening and extubation time, adverse events, total remifentanil and propofol consumptions and side effects were recorded. Heart rate and blood pressure were recorded during this period.

Conditions

Interventions

TypeNameDescription
DRUGRemifentanil0.1-0.5 mcg/kg/min infusion
DRUGPropofol75-200 mcg/kg/min infusion

Timeline

Start date
2015-01-01
Primary completion
2015-09-01
Completion
2015-09-01
First posted
2015-11-02
Last updated
2015-11-02

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT02593942. Inclusion in this directory is not an endorsement.